From :	Graeme Robertson <Graeme.Robertson@gilead.com>
To :	Maia Nikoleishvili <mnikoleishvili@moh.gov.ge>
Subject :	Re: [EXTERNAL] request from MoH Georgia
Cc :	Tamar Gabunia <tgabunia@moh.gov.ge>; m.tskitishvili@mrdi.gov.ge; Aysan Murtezaoglu <Aysan.Murtezaoglu@gilead.com>
Received On :	17.03.2020 12:48

Dear Maia, Thank you for your mail, my colleague Aysan in copy on this mail is managing requests from the region and will ensure your request gets to the right people in our clinical research teams. In the meantime did you contact Gilead through the Corona virus response e mail address that I gave to David Seergenko late last week. Aysan will also be able to guide you through the compassionate use supply of drug. I wish you all the best in this turbulent times Please let me know if you require any further assistance Best wishes Graeme Sent from my iPhone On 16 Mar 2020, at 17:39, Maia Nikoleishvili wrote: Dear Graeme, Hope you are doing well! I would like to kindly provide you with a letter signed by the Minister – Ms. Ekaterine Tikaradze regarding the possibility of engagement in the study of Remdesivir for the treatment of the patients with severe acute respiratory syndrome of COVID-19. We kindly ask you to assist us in obtaining the response to the request addressed to Dr. Daniel O'Day. Thank you in advance for continued support and partnership. Looking forward to hearing from you. With best regards, Maia Nikoleishvili MPA Acting Head of International Relations and Protocol Division of Administration Ministry of IDPs from the Occupied Territories, Labour, Health and Social Affairs of Georgia Address: 144 Tsereteli ave., 0159 Tbilisi, Georgia Tel.: +995 32 2510034 (0803) Cell phone: +995 577272713 E-mail: mnikoleishvili@moh.gov.ge DISCLAIMER If you have received this message in error, please contact the sender immediately by return e-mail and notify the sender and then delete this message (including any attachments) from your system. This communication and any attachments contain information which is confidential and may also be legally privileged. It is for the exclusive use of the intended recipient(s). If you are not the intended recipient(s) please note that any form of disclosure, distribution, copying or use of this communication or the information in it or in any attachments is strictly prohibited and may be unlawful. If your e-mail contains any personal information then we will process this according to our Privacy Statement located on Gilead.com. E-mail communications cannot be guaranteed to be secure or error free, as information could be intercepted, corrupted, amended, lost, destroyed, arrive late or incomplete, or contain viruses. Gilead does not accept liability for any such matters or their consequences. Anyone who communicates with Gilead by e-mail is taken to accept the risks in doing so. Gilead has taken every reasonable precaution to ensure that any attachment to this e-mail has been swept for viruses. However, Gilead cannot accept liability for any damage sustained as a result of viruses and would advise that you carry out your own virus checks before opening any attachment. Gilead Sciences Europe Ltd ; Registered as a limited company in England and Wales ; Registered number 5510315 Registered office: South Building ; 2 Roundwood Avenue ; Stockley Park ; Uxbridge ; UB11 1AF ; England